Mast Therapeutics Inc (MSTX) was Downgraded by Maxim Group to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Maxim Group advised their investors in a research report released on Sep 21, 2016.
Mast Therapeutics Inc opened for trading at $0.58 and hit $0.5988 on the upside on Tuesday, eventually ending the session at $0.59, with a gain of 0.22% or 0.0013 points. The heightened volatility saw the trading volume jump to 1,62,39,406 shares. Company has a market cap of $125 M.
In a different news, on Mar 30, 2015, Brandi Roberts (CFO) purchased 38,000 shares at $0.50 per share price.
Mast Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform to develop MST-188 (vepoloxamer) Injection the Company’s lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001 a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001’s potential to treat patients with preserved ejection fraction (HFpEF).